As life expectancy increases, the prevalence of age-related diseases will also increase. Efforts to develop therapies for age-related neurodegenerative diseases have yet to succeed in impacting disease pathogenesis; current treatments target only the symptoms, not the causes. To develop disease-modifying agents, some researchers aim to identify common features of neurodegenerative diseases that might provide clues to potential drug targets. On November 29, 2012, researchers investigating Alzheimer's, Parkinson's, and Huntington's diseases met at the New York Academy of Sciences to discuss one such feature—the effect of metals in neurodegenerative diseases—and to highlight clinical achievements using metal-binding compounds to influence disease progression. The symposium, Targeting Metals in Alzheimer's and Other Neurodegenerative Diseases, was presented by the Academy's Brain Dysfunction Discussion Group.